Androgen deficiency syndrome. Testicular hypogonadism NOS
Conditions
Interventions
Intervention 1: Control group: three intramusculare injection of Enanthate testosterone 250MG with three-week intervals. Intervention 2: Intervention group: four intramuscular injection of Enantha
Treatment - Drugs
Control group: three intramusculare injection of Enanthate testosterone 250MG with three-week intervals
Intervention group: four intramuscular injection of Enanthate testosterone 250 mg with two-week intervals
Sponsors
Department of Research & Technology, Ahwaz JundiShapur University of medical sciences
Eligibility
Sex/Gender
Male
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: inclusion criteria:Symptoms of androgen deficiency;Below normal rang of testosterone;age over 40 years exclusion criteria:
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erectile dysfunction, Sex Frequency. Timepoint: Baseline , 2 months after the first injection. Method of measurement: International Index of Erectile Function Questionnaire.;Fasting Blood Sugar -2hour post prandial- HemoglobinA1c. Timepoint: Baseline , 2 months after the first injection. Method of measurement: FBS(mg/dl), 2hPP(mg/dl), HbA1C(%).;Cholesterol, Triglyceride , High Density Lipoprotein, Low Density Lipoprotein. Timepoint: Baseline , 2 months after the first injection. Method of measurement: mg/dl.;Blood pressure. Timepoint: Baseline , 2 months after the first injection. Method of measurement: mmhg. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lower urinary tract symptom. Timepoint: Baseline , 2 months after the first injection. Method of measurement: International Prostate Symptom Score.;Depression, Sleep disorders, Fatigue. Timepoint: Baseline , 2 months after the first injection. Method of measurement: BECK QUESTIONNAIR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaser Abaszade, MD
Ahwaz JundiShapur University of medical sciences
Outcome results
None listed